Licensing agreements for innovator GLP1R drugs weigh in with over $6.2bn in 2024
GLP1R agonists are currently used for the treatment of type 2 diabetes (T2D) and obesity to stimulate insulin secretion and inhibit glucagon release.
Comment & Opinion
How personalised medicine can revolutionise contraception
Top 20 biopharmas’ market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots
GLP-1R market: a two-horse race
Colombia’s president signs law to strengthen pharmaceutical sector
Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy
